Article Versions Notes

Jie G-L, Peng L-X, Zheng M-M, Sun H, Wang S-R, Liu S-YM, Yin K, Chen Z-H, Tian H-X, Yang J-J, et al. Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers. 2023; 15(1):302. https://doi.org/10.3390/cancers15010302

Jie, Guang-Ling, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, and et al. 2023. "Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC" Cancers 15, no. 1: 302. https://doi.org/10.3390/cancers15010302

Jie, G.-L., Peng, L.-X., Zheng, M.-M., Sun, H., Wang, S.-R., Liu, S.-Y. M., Yin, K., Chen, Z.-H., Tian, H.-X., Yang, J.-J., Zhang, X.-C., Tu, H.-Y., Zhou, Q., Wong, C. C. L., & Wu, Y.-L. (2023). Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers, 15(1), 302. https://doi.org/10.3390/cancers15010302